secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-205009
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Q1 2026 net loss $19.9M; cash runway only through Q3 2026
---------------------------------------------------------------

- Net loss $19.9M vs net income $32.7M in Q1 2025 (which included $50M Nestlé payment).
- Cash and equivalents $29.8M as of March 31, 2026; expects to fund ops only through Q3 2026.
- R&D expenses $13.2M (up from $11.8M), G&A $8.1M (down from $11.9M); no manufacturing services expenses.
- SER-155 IST for immune checkpoint inhibitor-related enterocolitis enrollment complete (15 pts); data expected in coming weeks.
- SER-155 Phase 2 ready for allo-HSCT but seeking funding; SER-603 preclinical for IBD with IND-enabling activities ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526205009/0001193125-26-205009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526205009/d155025d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-205009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer